EMEA-002575-PIP01-19

Key facts

Active substance
BLU-667
Therapeutic area
Oncology
Decision number
P/0266/2019
PIP number
EMEA-002575-PIP01-19
Pharmaceutical form(s)
Capsule, hard
Condition(s) / indication(s)
Treatment of lung cancer (small cell and non-small cell lung cancer)
Route(s) of administration
Oral use
Contact for public enquiries
Blueprint Medicines (Netherlands) B.V.

E-mail: medinfo@blueprintmedicines.com
Tel. +31 858880230

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating